BioNova today announced that it has submitted an investigational new drug (IND) application for BN301 (STRO-001) for the treatment of hematologic malignancies to the China National Medical Products Administration (NMPA).
BioNova Pharmaceuticals Limited (BioNova) will present a poster for preclinical data of BN104 (BNM-1192) from its internal discovery portfolio at the upcoming Annual Meeting of 2022 American Association for Cancer Research (AACR) in New Orleans on April 8-13, 2022.
BioNova Pharmaceuticals Limited (BioNova) today announced that Center of Drug Evaluation (CDE) of National Medical Products Administration (NMPA) had approved its investigational new drug (IND) application for BN102 to conduct clinical trials in patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and B-cell Non-Hodgkin Lymphoma (NHL) in China.
BioNova today announced that it has submitted an investigational new drug (IND) application for BN102 for the treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and B-cell Non-Hodgkin Lymphoma (NHL) to the China National Medical Products Administration (NMPA).
Shanghai and Hong Kong, PRC, Nov. 22, 2021 - BioNova Pharmaceuticals Limited (BioNova) together with its joint venture subsidiary BK Pharmaceuticals Limited, today announced that it has filed a New Drug Application (NDA) for belumosudil for the treatment of chronic graft-versus-host disease (cGVHD) to the China National Medical Products Administration (NMPA).
Sutro Biopharma, Inc. (Sutro;NASDAQ: STRO)与烨辉医药今日联合宣布签署了授权协议,Sutro授权烨辉医药在大中华区(包括中国大陆、香港、澳门和台湾)开发和商业化靶向CD74的抗体偶联药物 (ADC) STRO-001,用于治疗血液癌症患者。
9 月 8 日,赛诺菲宣布将以$19 亿美元收购 Kadmon Holdings,Inc. (NASDAQ: KDMN),旨在将Rezurock™(belumosudil)纳入其移植产品系列中。目前,烨辉医药正在中国 7 家临床中心展开 belumosudil (BN101)针对 cGVHD 的临床二期试验,预计于 2021 年年底申报NDA。
2021年8月20日--中国上海,以研发和临床创新肿瘤药物为主的生物制药公司烨辉医药与业界领先的人工智能药物研发公司英矽智能,达成项目合作,双方将围绕特定靶点共同开发针对血液恶性肿瘤的小分子抑制剂。
近日,烨辉医药科技(上海)有限公司(以下简称“烨辉医药”)与药明康德子公司合全药业签署战略合作协议,携手加快烨辉医药创新药研发和生产进程。
NEW YORK, NY / ACCESSWIRE / July 16, 2021 - Kadmon Holdings, Inc. (Nasdaq:KDMN) today announced that the U.S. Food and Drug Administration (FDA) has approved REZUROCK™ (belumosudil) 200 mg once daily (QD) for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy.